Bulk Quote Inquiry

LIL-HM2B4-100μg / Inquiry

LIL-HM2B4-500μg / Inquiry

LIL-HM2B4-1mg / Inquiry

Human LILRB4/CD85k/ILT3 Protein

Product Info

Recombinant Human LILRB4/CD85k/ILT3 Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Gln22-Arg256.[Accession | AAH26309]

Molecular Weight

The protein has a predicted MW of 52.6 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by SEC-HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

Human LILRB4 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of Human LILRB4 is greater than 95% as determined by SEC-HPLC.


Immobilized Human LILRB4 at 0.2μg (100ul/Well) on the plate. Dose response curve for Human Anti-LILRB4 Antibody, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.


LILRB4,also known as CD85k and LIR-5, ILT3,  is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.


CD85 antigen-like family member K; CD85k antigen; CD85k; HM18; ILT3; ILT-3; ILT3CD85K; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB4; LIR5; LIR5LILRB5; LIR-5subfamily B, member 4; member 4


(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.

Kactus Biosystems Co.Ltd
Online Message